GO Term | Evidence Code | PMID |
---|---|---|
nervous system development | ||
purine nucleobase metabolic process | ||
ribonucleoside monophosphate biosynthetic process | ||
hypoxanthine biosynthetic process | ||
5-phosphoribose 1-diphosphate biosynthetic process |
GO Term | Evidence Code | PMID |
---|---|---|
ribose phosphate diphosphokinase complex | ||
cytosol |
|
|
cytoplasm |
Tissue with high expression from Human Protein Atlas. Tissues that are highly expressed are highlighted.
DO ID | Disease Name | Source |
---|---|---|
DOID:4766 | embryoma | |
DOID:4851 | pilocytic astrocytoma | |
DOID:5077 | subependymal giant cell astrocytoma | |
DOID:5604 | adult acute lymphocytic leukemia | |
DOID:5672 | large intestine cancer | |
DOID:5688 | Werner syndrome | |
DOID:5723 | optic atrophy | |
DOID:574 | peripheral nervous system disease | |
DOID:580 | uric acid nephrolithiasis | |
DOID:607 | paraplegia |
HPO ID | HPO Term |
---|---|
HP:0000028 | Cryptorchidism |
HP:0000047 | Hypospadias |
HP:0000083 | Renal insufficiency |
HP:0000154 | Wide mouth |
HP:0000218 | High palate |
HP:0000268 | Dolichocephaly |
HP:0000286 | Epicanthus |
HP:0000316 | Hypertelorism |
HP:0000325 | Triangular face |
HP:0000365 | Hearing impairment |
Disease ID | Disease Name |
---|---|
ORPHA:423479 |
|
OMIM:311070 |
|
ORPHA:411543 |
|
OMIM:301835 |
|
OMIM:304500 |
|
ORPHA:1187 |
|
ORPHA:411536 |
|
OMIM:300661 |
|
ORPHA:99014 |
|
Species | Gene ID | Alliance of Genome Resources | Orthologous MAtrix |
---|---|---|---|
115552517 | GADMO01075 | ||
101169709 | ORYLA01259 | ||
399237 | Xenbase:XB-GENE-1008574 | ||
394745 | Xenbase:XB-GENE-1008569 | ||
109306067 | CROPO18745 | ||
109310923 | CROPO18745 | ||
113446846 | PSETE19966 | ||
100083258 | ORNAN23088 | ||
100406823 | CALJA44847 | ||
105572401 | CERAT41487 |
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
GlyCosmos Portal v4.0.0
Last updated: August 19, 2024